The use of low-dose naltrexone as a therapeutic intervention for fibromyalgia has generated considerable interest among researchers and clinicians. Yet, the current evidence base remains mixed and demonstrates methodological heterogeneity across studies. The evidence suggests both promise and significant limitations that warrant careful examination and further investigation.
Table of contents
- Introduction
- Clinical trial evidence and efficacy outcomes
- Real-world effectiveness and patient-reported outcomes
- Mechanisms of action of low-dose naltrexone
- Inflammatory biomarker evidence
- Safety profile of low-dose naltrexone
- Systematic review conclusions
- Study limitations and future directions
- Conclusion
- References:
Introduction
Low-dose naltrexone (LDN) has attracted increasing clinical and research interest as a potential adjunctive therapy for fibromyalgia, particularly in view of ongoing unmet need and variable response to established treatments. Proposed mechanisms include modulation of neuroinflammatory pathways and altered pain processing, and a number of small trials and observational reports have suggested possible symptomatic benefit in some patients. However, the evidence base remains heterogeneous, with mixed findings across study designs and outcomes.
This article provides a structured review of the current evidence for LDN in fibromyalgia. It summarises results from randomised controlled trials, systematic reviews and meta-analyses, and real-world clinical data, and outlines the leading hypotheses regarding mechanism of action, including effects on microglial activity and inflammatory signalling. It also reviews the available safety data and highlights key limitations in the literature, with particular attention to sample size, follow-up duration, and outcome variability. Finally, it considers the implications for clinical practice and the importance of ongoing, adequately powered trials to clarify LDN’s role in fibromyalgia management.
Clinical trial evidence and efficacy outcomes
2025 meta-analysis: improvements vs baseline, but not clearly better than placebo
The evidence for LDN in fibromyalgia presents a complex and sometimes contradictory picture across recent systematic reviews and meta-analyses. A comprehensive 2025 systematic review and meta-analysis of eight randomised controlled trials found that, although LDN was associated with reduced pain compared with baseline [1]. These improvements were not superior to placebo when directly compared [1]. This finding suggests that while some symptom reduction occurs with LDN treatment, the clinical benefits may largely reflect placebo effects rather than specific pharmacological action.
2024 meta-analysis: pain scores and pressure pain threshold may improve
In contrast, another meta-analysis examining four randomised controlled trials with 222 fibromyalgia patients reported a significant reduction in pain scores favouring LDN over placebo [2]. Importantly, this analysis also documented a greater increase in pressure pain threshold among patients receiving LDN than among those receiving placebo [2]. This suggests that the potential benefits beyond subjective pain reporting. However, the fibromyalgia impact questionnaire, revised and pain catastrophising scale showed no significant differences between treatment groups [2].
2025 meta-analysis: pain benefit signal, but mixed findings on sensitivity measures
A third meta-analysis, incorporating five randomised controlled trials, found LDN to be superior to placebo in alleviating pain in both the primary and sensitivity analyses [3]. Notably, this analysis identified vivid dreams as a significantly more frequent adverse effect in the LDN-treated group than in the placebo group, with a relative risk of 2.41 [3]. The analysis did not support raising the mechanical pain threshold, which contrasts somewhat with earlier findings [3].
Exploring pain mechanisms (not just symptom scores)
One of the most rigorously designed trials, the randomized placebo-controlled FINAL trial involving 99 women with fibromyalgia, conducted a secondary analysis examining pain sensitivity mechanisms [4]. Of the five examined outcomes measuring spinal and supraspinal pain mechanisms, only the change in conditioned pain modulation (CPM) showed a significant between-group difference favouring LDN with greater enhancement [4]. However, sensitivity analyses suggested this group difference was partly explained by a decrease in CPM in the placebo group. No association was found between changes in CPM and clinical pain improvement, suggesting this may represent a random finding [4].
Danish crossover trial: no clinically relevant analgesic effect
A Danish double-blind, placebo-controlled crossover study with 58 patients found no clinically relevant analgesic efficacy of LDN treatment in fibromyalgia patients. The median differences in fibromyalgia impact questionnaire revised scores and summed pain intensity ratings showing no significant improvement [5].
Real-world effectiveness and patient-reported outcomes
Beyond randomised controlled trials, real-world clinical data provide additional insight into the effectiveness of LDN.
A 14-year enterprise-wide retrospective analysis from the Mayo Clinic examining 115 fibromyalgia patients found that 65% of those with follow-up data reported perceived benefit in their pain symptoms while taking LDN [6]. The final daily dose of oral LDN in this cohort ranged from 0.8 to 9.0 mg, with 4.5 mg once daily being the most common dose [6]. Notably, 36% of patients discontinued LDN at the most recent follow-up, and adverse effects were reported in only 11% [6].
Another retrospective utilisation review at a single Veterans Affairs institution found that patients with fibromyalgia specifically showed significantly lower pain scores at initial follow-up compared to baseline [7]. Of the 136 participants overall, 31.6% were maintained on LDN at an average dose of 3.8 mg by the end of the study, with 17.1% of patients achieving greater than or equal to 30% pain reduction from baseline [7].
Mechanisms of action of low-dose naltrexone
The theoretical basis for LDN’s efficacy in fibromyalgia involves multiple mechanisms that extend beyond traditional opioid receptor antagonism. At low doses (typically 1-5 mg daily), LDN appears to operate through distinct pharmacodynamic pathways compared to its conventional high-dose use [8]. One proposed mechanism involves transient blockade of opioid receptors followed by compensatory upregulation of endogenous opioid production, leading to increased levels of endogenous opioids, including beta-endorphins [9]. This “rebound effect” is thought to enhance endorphin signalling when the drug’s effects wear off.
More importantly, LDN is hypothesised to function as a glial cell modulator by antagonising Toll-like receptor 4 (TLR4) signalling [8], particularly within microglial cells. In vitro studies demonstrate that LDN can shift microglia from a highly activated pro-inflammatory phenotype to a quiescent anti-inflammatory M2 phenotype [10]. This shift is accompanied by cellular metabolic reprogramming involving transition from high glycolysis to mitochondrial oxidative phosphorylation (OXPHOS) [10]. Additionally, LDN appears to modulate mTOR/S6K expression in a dose-dependent manner, which underlies the cell metabolic phenotype and regulates microglia immune properties [10].
Inflammatory biomarker evidence
A pilot trial examining immune effects found that LDN was associated with reduced plasma concentrations of multiple pro-inflammatory cytokines including interleukin (IL)-1, IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p40, IL-12p70, IL-15, IL-17A, IL-27, interferon-gamma, transforming growth factor-beta, TNF-alpha, and granulocyte-colony stimulating factor [11]. This study also reported a 15% reduction in fibromyalgia-associated pain and an 18% reduction in overall symptoms after eight weeks of LDN treatment [11].
Safety profile of low-dose naltrexone
Regarding safety, a systematic review of nine studies (one randomised controlled trial, two case reports, two case series, and four pilot trials) found that LDN was generally effective for the symptomatic management of fibromyalgia. Of the 78% of included studies that evaluated safety, no severe adverse events were reported [12]. The most commonly reported adverse effects include vivid dreams and nausea, though these are typically mild and do not result in medication discontinuation [2]. In retrospective clinical analyses, adverse effects were reported in approximately 11% of patients and did not differ significantly from placebo with respect to serious adverse events, headache, diarrhoea, or dizziness [2].
Systematic review conclusions
A systematic review and narrative synthesis examining 21 papers, of which only five were prospective controlled trials, concluded that low-dose naltrexone may be an effective and safe pharmacotherapy for patients with fibromyalgia. However, current evidence lacks statistical power and multisite replication [13]. This synthesis emphasises the preliminary nature of the existing evidence base and the critical need for larger, more rigorous trials.
Study limitations and future directions
Several important limitations characterise the current evidence base. Most trials have small sample sizes, with many involving fewer than 100 participants [12]. The heterogeneity in study designs, intervention protocols, dosing regimens, follow-up periods, and outcome measures makes direct comparison and meta-analysis synthesis challenging. The duration of most clinical trials ranges from 8 to 12 weeks, which may be insufficient to fully characterise long-term effectiveness and potential tolerance development.
The INNOVA study, a planned phase III randomised double-blind placebo-controlled trial with 120 patients and a one-year follow-up period, represents an important advancement in evidence generation [14]. This study will assess not only pain intensity but also include comprehensive neurobiological investigations. This included brain MRI scanning, to examine changes in brain metabolites related to neuroinflammation and central sensitisation [14]. Such investigations are critical for validating the proposed mechanisms of action and identifying which fibromyalgia patients might most benefit from LDN therapy.
Conclusion
The evidence for low-dose naltrexone (LDN) in fibromyalgia is promising but not yet definitive. Early studies and small clinical trials suggest LDN may help reduce pain in some people, with potential benefits linked to inflammatory pathways and pain-sensitivity mechanisms. While results have been mixed and some findings have not consistently outperformed placebo, the overall signal is encouraging enough that larger, well-designed randomised controlled trials are now needed to confirm who benefits most and what the true size of the effect is [3].
LDN also appears to have a favourable safety profile, with side effects typically mild and manageable. Importantly, real-world clinical experience suggests a meaningful proportion of patients report symptomatic improvement. This supports ongoing interest in LDN as a potential option—particularly when standard treatments have not provided adequate relief. However, the current evidence base is still too limited to position LDN as a routine, first-line recommendation for fibromyalgia. Further research is required to clearly define its role in clinical practice [12].
References:
2025 meta-analysis: improvements vs baseline, but not clearly better than placebo
2024 meta-analysis: pain scores and pressure pain threshold may improve
2025 meta-analysis: pain benefit signal, but mixed findings on sensitivity measures
Exploring pain mechanisms (not just symptom scores)
Danish crossover trial: no clinically relevant analgesic effect
Real-world effectiveness and patient-reported outcomes
Mechanisms of action of low-dose naltrexone
[8] K. Toljan and B. Vrooman, “Low-Dose Naltrexone (LDN)Review of Therapeutic Utilization,” Multidisciplinary Digital Publishing Institute, Sep. 2018, doi: https://www.mdpi.com/2076-3271/6/4/82
Inflammatory biomarker evidence
Safety profile of low-dose naltrexone
Systematic review conclusions
Study limitations and future directions
Are weight loss treatments making you tired, or have they led to a sudden increase in hair loss? Do you struggle with sleep?
Get a free month’s supply of one of our compounded treatments for energy, hair loss or sleep, with your first purchase of Mounjaro or Wegovy from Medical Mojo.
Claim your FREE offer
